The Centers for Disease Control and Prevention published preliminary data Tuesday showing that more than one-third of individuals eligible for a commonly used HIV prevention drug received a prescription, as funding for a critical HIV program grew 16-fold between fiscal years 2019-2023.
But the reach of this strategy is highly inconsistent among racial groups.
Pre-exposure prophylaxis, or PrEP, is a drug used to reduce transmission of HIV after exposure, and is recommended for individuals at high risk of contracting HIV.
